Total Funding
32
Total FundingSeries C raised
Growth Score
pts
Heat Score
-9 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
See more interactive data and historical milestones on desktop for the best experience
106651
Dynacure is a clinical-stage drug development company focused on improving the lives of patients with rare and orphan diseases.
- Stéphane van Rooijen: Chief Executive Officer
- Frédéric Legros: Chief Operating Officer
About the Company
Dynacure is a clinical-stage drug development company focused on improving the lives of patients with rare and orphan diseases.The Dynacure team leverages its proven track record in rare disease drug development to build a pipeline of novel drugs. Dynacure is developing DYN101, an investigational antisense medicine designed to modulate the
expression of dynamin 2 for the treatment of Centronuclear Myopathies, with Ionis Pharmaceuticals. Dynacure is also building a complementary research portfolio targeting other orphan disorders.
